Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: A pilot study

Table 2 Prevalence (%) and mean titre of PCA and non-organ specific autoantibodies in HCV patients at three time-points.

	Before treatment (n = 57)		End of treatment (n = 57)		End of follow up (n = 57)		P value
	Pos (%)	Mean titre	Pos (%)	Mean titre	Pos (%)	Mean titre
ANA	54.4	1/188	70.2	1/194	71.9	1/171	NS
SMA	89.5	1/127	89.5	1/135	84.2	1/118	NS
Undefined	12.3	1/108	19.31	1/76	14	1/248	NS
cytoplasmic staining1
AMA	0		0		0
Anti-LKM	5.3	1/133	7	1/100	5.3	1/67	NS
PCA	15.8	1/76	17.5	1/108	15.8	1/231	NS
Anti-LC	1.8	1/40	3.5	1/60	0		NS
ANCA	80.7	1/31	80.7	1/31	82.5	1/31	NS
CANCA	78.9	1/28	77.2	1/30	77.2	1/28	NS
PANCA	3.5	1/90	5.3	1/53	8.8	1/64	NS
Anti-PR-3	0		0		0
Anti-MPO	0		0		0
Anti-dsDNA	22.8	129 BI	24.6	135 BI	21.1	134 BI	NS
Anti-CL	19.3	148 BI	29.8	138 BI	17.5	129 BI	NS

Abbreviations are same as in the text. pANCA = ANCA with perinuclear pattern, NS = not statistically significant, n = the number of individuals studied in each group. P values were calculated by one-way analysis of variance for the mean titres and by total χ² for autoantibodies positivity.

¹Means an AMA-like pattern by indirect immunofluorescense on HEp-2 cells, which did not give an AMA pattern on frozen liver, renal and stomach sections and which did not react in specific ELISA for AMA and immunoblots on human liver.